Dimethyl Sulfoxide
Apexbio Technology LLC Regorafenib 755037-03-7 10mM (in 1mL DMSO)
Regorafenib (CAS 755037-03-7) is an orally bioavailable inhibitor targeting multiple receptor tyrosine kinases (RTKs) such as VEGFR1/2/3 PDGFR Kit RET Raf-1 B-RAF and B-RAFV600E By impeding kinase phosphorylation (IC50 values ranging from approximately 1 5 46 nM) regorafenib disrupts signaling pathways associated with angiogenesis tumor cell proliferation and metastasis Preclinically regorafenib inhibited VEGFR2 phosphorylation (IC50 3 nM) and reduced VEGF-induced endothelial cell proliferation in vitro In rodent tumor xenograft models it demonstrated dose-dependent tumor growth suppression and antimetastatic potential supporting its utility for oncology research
Apexbio Technology LLC Zalcitabine 7481-89-2 10mM (in 1mL DMSO)
Zalcitabine is a nucleoside analog inhibitor targeting viral reverse transcriptase a key enzyme promoting viral replication By competitively binding to the active site of reverse transcriptase zalcitabine terminates DNA chain elongation effectively inhibiting viral DNA synthesis In vitro studies have demonstrated inhibitory activity against HIV-1 with reported IC50 values ranging approximately from 0 03 to 0 3 M Zalcitabine is frequently utilized in biomedical research as an antiviral reference molecule for studying HIV therapeutic targets antiviral drug resistance and mechanisms of reverse transcription inhibition
Apexbio Technology LLC PF-04449913 1095173-27-5 10mM (in 1mL DMSO)
PF-04449913 (CAS 1095173-27-5) is an orally bioavailable small molecule inhibitor targeting smoothened (SMO) a critical component of the Hedgehog (Hh) signaling pathway Activation of SMO by Hh ligands typically initiates signaling cascades involving Gli transcription factors influencing cellular proliferation and oncogenesis PF-04449913 inhibits SMO activity with an IC50 of 5 nM thereby suppressing downstream Gli-mediated signaling Preclinical pharmacokinetic studies demonstrated favorable properties including a half-life of approximately 30 hours 55% oral bioavailability low plasma clearance (1 03 mL/min/kg) and moderate distribution (2 7 L/kg) PF-04449913 is actively explored in cancer research contexts
Apexbio Technology LLC Linezolid(Synonyms: Zyvox, Zyvoxid, U-100766, PNU-100766, U-100766E, PNU100766, Linezolide), 10mM (in 1mL DMSO), CAS: 165800-03-3.
Linezolid (CAS 165800-03-3) is a synthetic oxazolidinone antimicrobial compound with broad-spectrum activity primarily against Gram-positive bacteria including multi-drug resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA) vancomycin-resistant Enterococcus (VRE) and penicillin-resistant Streptococcus pneumoniae Linezolid inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit thereby preventing formation of the functional 70S initiation complex In cell-free transcription-translation assays using E coli linezolid demonstrates an IC50 of approximately 1 8 mM Due to its pharmacokinetics and high oral bioavailability linezolid is widely utilized in clinical research related to complicated skin infections and bacterial pneumonia